Jpmorgan Chase & CO Design Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 14,184 shares of DSGN stock, worth $75,458. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,184

Previous 38,704 63.35%

Holding current value

$75,458

Previous $155,000 69.68%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$3.23 - $4.77 $79,199 - $116,960	-24,520 Reduced 63.35%	14,184 $47,000
Q1 2024 May 10, 2024	SELL	$2.27 - $4.03 $5,802 - $10,300	-2,556 Reduced 6.19%	38,704 $155,000
Q4 2023 Feb 12, 2024	SELL	$1.99 - $2.76 $30,013 - $41,626	-15,082 Reduced 26.77%	41,260 $109,000
Q3 2023 Nov 14, 2023	BUY	$2.05 - $8.14 $8,935 - $35,482	4,359 Added 8.39%	56,342 $132,000
Q2 2023 Aug 11, 2023	BUY	$4.99 - $7.64 $129,874 - $198,846	26,027 Added 100.27%	51,983 $327,000
Q1 2023 May 18, 2023	BUY	$5.5 - $9.77 $142,758 - $253,590	25,956 New	25,956 $149,000
Q4 2022 Feb 13, 2023	SELL	$7.86 - $17.2 $576,546 - $1.26 Million	-73,352 Reduced 78.74%	19,800 $203,000
Q3 2022 Nov 14, 2022	BUY	$14.09 - $25.57 $1.05 Million - $1.91 Million	74,863 Added 409.33%	93,152 $1.56 Million
Q2 2022 Aug 11, 2022	SELL	$9.91 - $17.33 $19,324 - $33,793	-1,950 Reduced 9.63%	18,289 $256,000
Q1 2022 May 11, 2022	BUY	$11.17 - $20.89 $50,309 - $94,088	4,504 Added 28.62%	20,239 $327,000
Q4 2021 Feb 10, 2022	BUY	$13.64 - $21.41 $103,636 - $162,673	7,598 Added 93.38%	15,735 $337,000
Q3 2021 Nov 12, 2021	BUY	$13.99 - $20.03 $113,836 - $162,984	8,137 New	8,137 $120,000

Others Institutions Holding DSGN

# of Institutions

102

Shares Held

31.9M

Call Options Held

1.1K

Put Options Held

21.3K

View Full List

About Design Therapeutics, Inc.

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $297M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

More about DSGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Design Therapeutics, Inc. Transaction History